Nagoya Protocol Compliance: A Practical Guide for EU Companies
Whether you're in pharma, biotech, cosmetics, food, or research, understanding and implementing Nagoya Protocol compliance is essential. This guide walks you through what the Nagoya Protocol is, who it applies to, and how to build a robust Access and Benefit-Sharing (ABS) compliance system in your organisation.
What is the Nagoya Protocol?
The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization (ABS) is a supplementary agreement to the Convention on Biological Diversity (CBD). Adopted in 2010 and entering into force on 12 October 2014, it aims to ensure that benefits from the use of genetic resources are shared fairly and equitably with the countries and communities that provide those resources. The protocol establishes a framework for access and benefit-sharing (ABS) to address the historical inequity where developed countries have commercialized genetic resources from developing countries without adequate compensation. "Fair and equitable benefit-sharing" means that when genetic resources are accessed and utilized, the provider countries receive a share of the benefits, which can include monetary payments, technology transfer, capacity building, or other forms of compensation. This framework promotes biodiversity conservation and sustainable use by creating incentives for countries to protect their genetic resources.
Key takeaway: The Nagoya Protocol ensures that if your organisation uses genetic resources from a particular country, those benefits (financial or otherwise) are shared fairly with the source country and the local communities involved.
Who Does the Nagoya Protocol Apply To?
Industries and Sectors Covered
The Nagoya Protocol applies to a wide range of industries that utilize genetic resources in their operations. Pharmaceutical companies often source natural compounds for drug development, such as plant-derived alkaloids or microbial metabolites. Biotech firms may use genetic material for research and product development, including enzymes or DNA sequences. Cosmetics manufacturers frequently incorporate plant extracts, essential oils, or other natural ingredients derived from biodiversity. Food and beverage companies utilize traditional crop varieties, wild relatives of cultivated plants, or microorganisms for fermentation processes. Agricultural enterprises may access genetic resources for breeding programs or biopesticides. Research institutions and universities conduct studies involving biological samples from various origins. Any organization that acquires genetic resources after 29 October 2014 for research, development, or commercialization falls under the protocol's scope, requiring compliance with ABS obligations.
What Counts as a Genetic Resource?
Genetic resources are defined under the Nagoya Protocol as any material of plant, animal, microbial, or other origin containing functional units of heredity, such as genes or DNA sequences, that have actual or potential value for humanity. This includes whole organisms, parts of organisms, or derivatives that contain genetic information. However, the protocol excludes human genetic resources and fermented products like beer or yogurt, as they no longer contain functional units of heredity. The distinction between genetic resources and derivatives is important: genetic resources are the original biological materials, while derivatives are products developed from them, such as pharmaceuticals or GMOs. The concept of "origin" refers to the country where the genetic resource was first accessed, which determines the applicable national ABS legislation. For resources accessed before the protocol's entry into force, different rules may apply depending on national laws.
EU ABS Regulation 511/2014: Key Obligations
Due Diligence Obligations
Due diligence under EU ABS Regulation 511/2014 requires users of genetic resources to take reasonable steps to ensure that the resources were accessed legally and that benefits are shared appropriately. This involves collecting and maintaining information about the genetic resources used, including their origin, date of access, and compliance with applicable ABS legislation. Users must verify Prior Informed Consent (PIC) from the provider country and Mutually Agreed Terms (MAT) that outline benefit-sharing arrangements. This information must be transferred to subsequent users in the supply chain, creating a chain of custody. Due diligence is not just a one-time check but an ongoing process that includes risk assessments and documentation. For EU-based users, this means implementing systems to track genetic resources throughout their lifecycle and ensuring compliance with both EU and provider country requirements.
The DECLARE System
The EU's DECLARE system is an online platform for reporting the utilization of genetic resources under Regulation 511/2014. Users must submit declarations for genetic resources accessed after 29 October 2014, providing details such as the resource description, country of origin, date of access, and intended use. Declarations are required before commercialization or within 6 months of first utilization, whichever comes first. The system facilitates transparency and allows competent authorities to monitor compliance. Regular reporting is mandatory for ongoing utilization, with updates required annually or when significant changes occur. Information submitted includes PIC and MAT details, ensuring that benefit-sharing obligations are met. The DECLARE system helps prevent illegal access and promotes fair benefit-sharing across the EU.
Penalties for Non-Compliance
Non-compliance with EU ABS Regulation 511/2014 can result in severe penalties, including administrative fines up to €500,000 or 4% of annual turnover, whichever is higher. National authorities may impose additional sanctions, such as product bans or withdrawal from the market. Enforcement mechanisms vary by EU member state, with some countries having dedicated ABS inspectors. Beyond financial penalties, non-compliance carries significant reputational risks, potentially damaging relationships with suppliers, customers, and investors. Notable cases include fines imposed on companies for failing to declare genetic resources, highlighting the importance of robust compliance systems. In extreme cases, criminal penalties may apply if intentional non-compliance is proven, underscoring the need for proactive ABS management.
Step-by-Step: Building an ABS Compliance System
Step 1: Identify Your Genetic Resource Use
Audit your R&D pipelines, manufacturing processes, and sourcing channels to determine which products, ingredients, or research areas involve genetic resources. Document the source materials, dates of acquisition, and geographic origins.
Step 2: Trace the Origin and Access Date
Determine when and where each genetic resource was accessed. The Nagoya Protocol applies to resources accessed after 29 October 2014. Collect documentation from suppliers and trace back through your supply chain.
Step 3: Verify Applicable ABS Legislation
For each genetic resource, research the ABS legislation of the source country. Some countries have specific requirements for Prior Informed Consent (PIC) and Mutually Agreed Terms (MAT). Ensure all applicable requirements have been met.
Step 4: Establish Due Diligence Procedures
Develop standard operating procedures for collecting, recording, and transferring ABS information. Include supplier questionnaires, due diligence documentation templates, and an internal system for tracking compliance status.
Step 5: Document and Maintain Records
Keep comprehensive records of all genetic resources, their origins, PIC and MAT agreements, and your due diligence process. These records must be retained for at least 5 years and made available to regulatory authorities upon request.
Common Compliance Challenges
Organizations face several common challenges in achieving Nagoya Protocol compliance. One major issue is the lack of comprehensive supply chain documentation, making it difficult to trace the origin of genetic resources back to their source countries. Many suppliers may not provide adequate ABS information, requiring users to conduct extensive due diligence. Tracing origins becomes complicated when resources have passed through multiple intermediaries, potentially in different countries. There's often confusion about what constitutes genetic resources versus derivatives, leading to uncertainty about applicability. Supplier cooperation can be inconsistent, especially with international partners unfamiliar with ABS requirements. Additionally, the evolving nature of national ABS legislation in provider countries creates ongoing compliance challenges. Building internal expertise and implementing systematic tracking processes are essential to overcome these hurdles.
How 3BIO Can Help
3BIO specialises in helping organisations navigate the complexities of Nagoya Protocol and EU ABS Regulation compliance. Our services include:
- ABS Audits: Comprehensive assessment of your current compliance status and identification of gaps
- Due Diligence System Design: Development of tailored SOPs and documentation systems
- Training: Staff education on ABS obligations and practical compliance procedures
- PIC & MAT Support: Assistance in securing and documenting Prior Informed Consent and Mutually Agreed Terms
- ABS Tools: Access to our proprietary compliance tools and databases
Visit our Biodiversity services page to learn more about our ABS offerings, or contact us to discuss your specific situation.
Frequently Asked Questions
Q: What is the Nagoya Protocol?
A: The Nagoya Protocol is a supplementary agreement to the Convention on Biological Diversity (CBD), adopted in 2010 and entering into force in 2014. It establishes a framework for Access and Benefit-Sharing (ABS) — ensuring that benefits arising from the use of genetic resources are shared fairly and equitably with the countries and communities that provide those resources.
Q: Does the Nagoya Protocol apply to my company?
A: The Nagoya Protocol applies to any organisation that uses genetic resources — biological material of plant, animal, microbial or other origin containing functional units of heredity. This includes pharmaceutical companies using natural compounds, cosmetics manufacturers using plant extracts, food companies using traditional crop varieties, and research institutions working with biological samples. If your R&D, manufacturing, or product development involves genetic resources accessed after October 2014, you likely have ABS obligations.
Q: What is EU ABS Regulation 511/2014?
A: EU Regulation 511/2014 implements the Nagoya Protocol within the European Union. It requires users of genetic resources to exercise due diligence to ascertain that resources were accessed in accordance with applicable ABS legislation, and to transfer relevant information to subsequent users. Non-compliance can result in significant fines and reputational damage.
Q: How can 3BIO help with Nagoya Protocol compliance?
A: 3BIO provides end-to-end Nagoya Protocol compliance services including ABS audits to assess your current compliance status, due diligence system design, staff trainings, assistance with Prior Informed Consent (PIC) and Mutually Agreed Terms (MAT) negotiations, and access to our proprietary ABS compliance tools. Contact us to discuss your specific situation.
Talk to Our ABS Experts
Ready to strengthen your Nagoya Protocol compliance? Our biodiversity experts are here to help.
Schedule a ConsultationOr email us at info@3bio.eu